Reunion Neuroscience appoints Sahil V. Kirpekar, M.D., as President and CEO to lead the company's clinical development strategy in psychiatric and psychedelic medicine

Reunion Neuroscience appoints Sahil V. Kirpekar, M.D., as President and CEO, signaling a leadership change at a company focused on psychiatric and psychedelic medicine. The move centers on corporate strategy, clinical development, and execution as the company advances its drug pipeline. Kirpekar's role likely includes guiding development programs, investor-facing priorities, and organizational growth in a biotech setting where leadership experience can shape regulatory planning and commercialization prospects. Reunion Neuroscience operates in a sector linking neuroscience, mental health treatment, and psychedelic-inspired therapeutics, so the appointment matters as a marker of how the company plans to position itself in a competitive clinical landscape. The leadership transition also reflects broader maturation across psychedelic biotech, where executive hires often indicate preparation for later-stage trials, partnerships, financing, or strategic refocusing.